Ibudilast in Progressive MS : SPRINT-MS
Ibudilast for Progressive Multiple Sclerosis (SPRINT-MS, NN102)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis
Washington University is looking for people with MS to participate in a research study to evaluate the effects of Ibudilast on Primary or Secondary Progressive MS.
Purpose: We are doing this study to find out if the study drug can help people with progressive multiple sclerosis. We will also find out if it is safe to take without causing too many side effects.
Participation: This study lasts about 26 months and requires a total of 13 visits to Washington University. Study participants are randomly assigned to receive either the study drug or a placebo. There is an equal chance of receiving either the study drug or placebo. The study drug will be taken by mouth twice daily.
You may qualify to participate if you:
- Are between the ages of 21-65 years old
- Have been diagnosised with either Primary or Secondary Progressive MS
- Have had gradual worsening of symptoms in the past 1-2 years
- Able to walk independently or with assistance